[1] BURNS W,CHAUDHARI B P,HAFFNER D N.Neurogenetic and metabolic mimics of common neonatal neurological disorders[J].Semin Pediatr Neurol,2022,42:100972-100982.
[2] SIEGERT S,MINDLER G T,BRVCKE C,et al,Expanding the phenotype of the FAM149B1-Related ciliopathy and identification of three neurogenetic disorders in a single family[J].Genes(Basel),2021,12(11):1648-1663.
[3] HELLEBREKERS D M J,VAN ABEELEN S A M,CATSMAN C E,et al.Cognitive and behavioral functioning in two neurogenetic disorders;how different are these aspects in Duchenne muscular dystrophy and Neurofibromatosis type 1[J]? PLoS One,2022,17(10):0275803-0275826.
[4] HICKMAN R A,O'SHEA S A,MEHLER M F,et al,Neurogenetic disorders across the lifespan:from aberrant development to degeneration[J].Nat Rev Neurol,2022,18(2):117-124.
[5] GOOD J M,ATALLAH I,CASTRO JIMENEZ M,et al.NGS-based diagnosis of treatable neurogenetic disorders in adults:opportunities and challenges[J].Genes(Basel),2021,12(5):695-702.
[6] SEIDLITZ J,NADIG A,LIU S,et al.Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders[J].Nat Commun,2020,11(1):3358-3372.
[7] VAN EEGHEN A M,BRUINING H,WOLF N I,et al.Personalizedmedicine for rare neurogenetic disorders:can we make it happen[J]?Cold Spring Harb Mol Case Stud,2022,8(2):a006200-a006214.
[8] BENSON M D,WADDINGTON-CRUZ M,BERK J L,et al.Inotersen treatment for patients with hereditary transthyretin amyloidosis[J].N Engl J Med,2018,379(1):22-31.
[9] HERRERA-AROZAMENA C,MARTÍ-MARÍ O,ESTRADA M,et al.recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases[J].Molecules,2016,21(9):1165-1186.
[10] JOSHI C R,LABHASETWAR V,GHORPADE A.Destination brain:the past,present,and future of therapeutic gene delivery[J].J Neuroimmune Pharmacol,2017,12(1):51-83.
[11] COOREY B A,GOLD W A.Gold,breaking boundaries in the brain-advancesin editing tools for neurogenetic disorders[J].Front Genome Ed,2021,3:623519-623525.
[12] ANDERSON W F,BLAESE R M,CULVER K.The ADA human gene therapy clinical protocol:Points to consider response with clinical protocol,July 6,1990[J].Hum Gene Ther,1990,1(3):331-362.
[13] WANG D,TAI P W L,GAO G.Adeno-associated virus vector as a platform for gene therapy delivery[J].Nat Rev Drug Discov,2019,18(5):358-378.
[14] LISOWSKI L,DANE A P,Chu K,et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model[J].Nature,2014,506(7488):382-386.
[15] AL-ZAIDY S A,KOLB S J,LOWES L,et al.AVXS-101(Onasemnogene Abeparvovec)for SMA1:Comparative study with a prospective natural history cohort[J].J Neuromuscul Dis,2019,6(3):307-317.
[16] CAIN J T,LIKHITE S,WHITE K A,et al.Gene therapy corrects brain and behavioral pathologies in CLN6-Batten dsease[J].Mol Ther,2019,27(10):1836-1847.
[17] TARDIEU M,ZÉRAH M,GOUGEON M L,et al.Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome:an uncontrolled phase1/2 clinical trial[J].Lancet Neurol,2017,16(9):712-720.
[18] VAN ESCH H.MECP2 Duplication syndrome[J].Mol Syndromol,2012,2(3-5):128-136.
[19] CHEON C K,LIM S H,KIM Y M,et al.Autosomal dominant transmission of complicated hereditary spastic paraplegia due to a dominant negative mutation of KIF1A,SPG30 gene[J].Sci Rep,2017,7(1):12527-12538.
[20] GLORIOSO J C,COHEN J B,CARLISLE D L,et al,Moving toward a gene therapy for Huntington's disease[J].Gene Ther,2015,22(12):931-933.
[21] BANAKAR R,SCHUBERT M,COLLINGWOOD M,et al,Comparison of CRISPR-Cas9/Cas12a ribonucleoprotein complexesfor genome editing efficiency in the rice phytoene desaturase(OsPDS)gene[J].Rice(N Y),2020,13(1):4-11.
[22] NIEMIEC E,HOWARD H C.Howard,Germline genome editing research:what are gamete donors(not)informed about in consent forms[J]?CRISPR J,2020,3(1):52-63.
[23] YLA-HERTTUALA,S.CRISPR/Cas9 and p53:An odd couple requiring relationship management[J].Mol Ther,2018,26(12):2711.
[24] WILSON K E,FISH A M,MANKIW C,et al.Modeling familial predictors of proband outcomes in neurogenetic disorders:initial application in XYY syndrome[J].J Neurodev Disord,2021,13(1):12-24.
[25] REILLY M M,HERRMANN D N,PAREYSON D,et al.Trials for slowly progressive neurogenetic diseases need surrogate endpoints[J].Ann Neurol,2023,93(5):906-910.
[26] DOIG D,THORNE L,REES J,et al.Clinical,imaging and neurogenetic features of patients with gliomatosis cerebri referred to a tertiary neuro-oncology centre[J].J Pers Med,2023,13(2):222-232.
[27] FENG J,ZHANG L,CHEN C,et al.A cognitive neurogenetic approach to uncovering the structure of executive functions[J].Nat Commun,2022,13(1):4588-4607.
[28] MILLER A P,GIZER I R.Dual-systems models of the genetic architecture of impulsive personality traits:Neurogenetic evidence of distinct but related factors[J].MedRxiv,2023,2(10):23285725.
[29] GLASSON E J,BUCKLEY N,CHEN W,et al.Systematic review and meta-analysis:mental health in children with neurogenetic disorders associated with intellectual disability[J].J Am Acad Child Adolesc Psychiatry,2020,59(9):1036-1048.
[30] CHURCH G M,GAO Y,KOSURI S.Next-generation digital information storage in DNA[J].Science,2012,337(6102):1628-1629. |
